Innovent reports positive data of Tyvyt in HCC trial
Participants with HCC received Tyvyt plus Byvasda or sorafenib during the trial. Credit: Yale Rosen.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more